Becton, Dickinson and Company (NYSE:BDX) Q1 2024 Earnings Call Transcript February 1, 2024 Becton, Dickinson and Company beats earnings expectations. Reported EPS is $2.68, expectations were $2.39. Becton, Dickinson and Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome […]
Plus: H+H to extend affiliation deal with SUNY Downstate for up to $24.7M Jewish Board files layoff notice for Bronx, Westchester locations Brooklyn menopause telehealth startup raises $3.8M seed round
Janssen Submits New Drug Application to U.S. FDA for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium (BUSINESS WIRE) The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVI.